Gabrielle Abbott, Lisa-Marie Greenwood, Jessica G Bartschi, Suraya Dunsford, Isabella Goodwin, Anastasia Paloubis, Marianna Quinones-Valera, Eugene McTavish, Antonio Verdejo-Garcia, Janna Cousijn, Gary C K Chan, Nadia Solowij, Valentina Lorenzetti
{"title":"Social cognition in young adults who endorse a cannabis use disorder.","authors":"Gabrielle Abbott, Lisa-Marie Greenwood, Jessica G Bartschi, Suraya Dunsford, Isabella Goodwin, Anastasia Paloubis, Marianna Quinones-Valera, Eugene McTavish, Antonio Verdejo-Garcia, Janna Cousijn, Gary C K Chan, Nadia Solowij, Valentina Lorenzetti","doi":"10.1007/s00213-025-06890-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Cannabis use disorder (CUD) affects over 50 million people globally. Emerging evidence shows that some people with CUD may experience altered social cognition (e.g., emotion recognition or differentiation). These impairments can affect their ability to understand others' emotional states and navigate social interactions, potentially contributing to chronic cannabis use, even when it leads to interpersonal problems. However, the literature on social cognition in cannabis users is inconsistent, based on a paucity of studies, and characterised by methodological issues including conflation of remitted and current CUD (i.e., does not consider abstinence effects on cognition), limited assessment of cannabis metrics (e.g., dosage) and confounds entrenched with CUD (e.g., nicotine/alcohol use, anxiety).</p><p><strong>Objectives/methods: </strong>We aimed to examine social cognition (i.e., emotion recognition and differentiation, immediate/delayed face memory) in relation to endorsement of CUD (n = 83) vs. controls (n = 32), and measures of level of problematic cannabis use (i.e., Cannabis Use Disorder Identification Test - Revised; CUDIT-R) and dosage (i.e., cannabis grams/past month), accounting for hours since last cannabis use, nicotine/alcohol use, and trait anxiety.</p><p><strong>Results: </strong>There were no significant effects of CUD (d = 0-0.314) or dosage and level of problematic cannabis use on social cognition.</p><p><strong>Conclusions: </strong>Altered social cognition may not be a key feature of CUD, or the relationship between CUD and cognition may be moderated by factors such as age, treatment seeking, education, and IQ. In this study, younger age and higher education or IQ may have served as protective factors against social alterations. Replication studies are required to validate this notion.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06890-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: Cannabis use disorder (CUD) affects over 50 million people globally. Emerging evidence shows that some people with CUD may experience altered social cognition (e.g., emotion recognition or differentiation). These impairments can affect their ability to understand others' emotional states and navigate social interactions, potentially contributing to chronic cannabis use, even when it leads to interpersonal problems. However, the literature on social cognition in cannabis users is inconsistent, based on a paucity of studies, and characterised by methodological issues including conflation of remitted and current CUD (i.e., does not consider abstinence effects on cognition), limited assessment of cannabis metrics (e.g., dosage) and confounds entrenched with CUD (e.g., nicotine/alcohol use, anxiety).
Objectives/methods: We aimed to examine social cognition (i.e., emotion recognition and differentiation, immediate/delayed face memory) in relation to endorsement of CUD (n = 83) vs. controls (n = 32), and measures of level of problematic cannabis use (i.e., Cannabis Use Disorder Identification Test - Revised; CUDIT-R) and dosage (i.e., cannabis grams/past month), accounting for hours since last cannabis use, nicotine/alcohol use, and trait anxiety.
Results: There were no significant effects of CUD (d = 0-0.314) or dosage and level of problematic cannabis use on social cognition.
Conclusions: Altered social cognition may not be a key feature of CUD, or the relationship between CUD and cognition may be moderated by factors such as age, treatment seeking, education, and IQ. In this study, younger age and higher education or IQ may have served as protective factors against social alterations. Replication studies are required to validate this notion.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
